The mature European IC device market will be limited by declining ASPs due to a number of factors, including intense price competition. Moreover, the COVID-19 pandemic will have a negative impact on procedure volumes and market growth in 2020. However, rising uptake of next-generation DES and BRS later in the forecast period and increasing PCI volumes will mitigate these declines to some extent.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for IC devices in Europe across a 10-year period.
The European IC device market will be impacted by the COVID-19 pandemic in the short term.
What guidance or recommendations have been issued for IC procedures in the face of infection containment and self-isolation measures?
How will the pandemic impact clinical trials and product launches?
How quickly will procedure volumes recover?
The exclusive applicability of MDR in Europe will result in more stringent regulatory requirements.
What are the changes under the MDR that will affect the IC device market.
How will this impact the small and mid-sized emerging companies in the IC device market?
How will this impact pipeline products and when are they expected to launch?
The continued launch of newer BRS and DCBs will drive a shift in device preference in procedures that have traditionally been performed with DES or BMS, respectively.
How are current recommendations for use dictating adoption of DES, BMS, and BRS for CAD patients?
What is the evolving role of DCBs in PCIs in the current clinical landscape?
What has been the impact of the launch of Abbott Laboratories' XIENCE Sierra on the DES market?
The accessory device segment is poised to see slight growth due to an increasing focus on specialty devices for treating complex PCIs.
In which segments of the accessory device market have competitors focused their product development efforts?
How will aggregate ASPs be affected by the emerging market for specialized guidewires, microcatheters, and reentry and recanalization devices?
What are current clinical practices surrounding CTO-PCI, and how do these practices affect accessory device use during these procedures?
Price competition will limit revenue growth potential, especially in light of increased cost consciousness among health care facilities.
How will ASP trends vary by country?
What are the effects of government-driven pricing pressure on ASPs, and which product segments will be most impacted?
Which segments will experience the most price competition?
- Interventional Cardiology Devices - Market Insights - Europe
Author(s): Sangeetha Iyer, Pharm.D
Sangeetha Iyer is an analyst within the Cardiovascular Medtech Insights team at Decision Resource Group, specializing in structural heart closure and vascular access device markerts across the Asia Pacific region, as well as medical device pricing and regulations in China and Japan. Sangeetha has represnted India at the European Society of Cardiology confrerence in Greece(2016) and Sweden(2017), where her research poster was awarded the top prize. Sangeetha holds a Doctor of Pharmacy degree from the Manipal Academy of Higher Education. Follow Sangeetha on twitter: @Slyer_DRG